NO EVIDENCE OF R7128 DRUG RESISTANCE AFTER UP TO 4 WEEKS TREATMENT OF GT 1, 2 AND 3 HEPATITIS C VIRUS INFECTED INDIVIDUALS

被引：7
|
作者：
Le Pogam, S. [1 ]
Seshaadri, A. [1 ]
Kosaka, A. [1 ]
Hu, S. [1 ]
Beard, A.
Julian, S. [1 ]
Nick, C. [1 ]
Najera, I. [1 ]
机构：
[1] Roche Palo Alto LLC, Palo Alto, CA USA
来源：
JOURNAL OF HEPATOLOGY | 2009年 / 50卷
关键词：
D O I：
10.1016/S0168-8278(09)60960-0
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
958
引用
收藏
页码：S348 / S348
页数：1
相关论文
共 50 条
  • [31] High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV genotype 1b
    Hidenori Toyoda
    Takashi Kumada
    Seiki Kiriyama
    Makoto Tanikawa
    Yasuhiro Hisanaga
    Akira Kanamori
    Toshifumi Tada
    Takahiro Arakawa
    Masashi Fujimori
    Takuro Niinomi
    Naoto Ando
    Satoshi Yasuda
    Keisuke Sakai
    Jun Kimura
    Journal of Gastroenterology, 2011, 46 : 501 - 509
  • [32] Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2and 3 in northwest China
    Ying Yang
    Feng-Ping Wu
    Wen-Jun Wang
    Juan-Juan Shi
    Ya-Ping Li
    Xin Zhang
    Shuang-Suo Dang
    World Journal of Gastroenterology, 2019, (44) : 6551 - 6560
  • [33] Hepatocyte nuclear factor (HNF) 1 and HNF4 mediate hepatic multidrug resistance protein 2 up-regulation during hepatitis C virus gene expression
    Qadri, Ishtiaq
    Iwahashi, Mieko
    Kullak-Ublick, Gerd A.
    Simon, Francis R.
    MOLECULAR PHARMACOLOGY, 2006, 70 (02) : 627 - 636
  • [34] Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies
    Kumada, Hiromitsu
    Mochida, Satoshi
    Suzuki, Fumitaka
    Chayama, Kazuaki
    Karino, Yoshiyasu
    Nakamura, Keisuke
    Fujimoto, Go
    Howe, Anita Y. M.
    Ludmerer, Steve W.
    Mobashery, Niloufar
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 (10) : 1674 - 1683
  • [35] Resistance of hepatitis C virus to NS3-4A protease inhibitors:: Mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations
    Courcambeck, Jerome
    Bouzidi, Mourad
    Perbost, Regis
    Jouirou, Besma
    Amrani, Nolwenn
    Cacoub, Patrice
    Pepe, Gerard
    Sabatier, Jean-Marc
    Halfon, Philippe
    ANTIVIRAL THERAPY, 2006, 11 (07) : 847 - 855
  • [36] Changes in NS3/4A and NS5A resistance-associated variants of hepatitis C virus after treatment failure with direct-acting antiviral(s)
    Hai, Hoang
    Yoshida, Kanako
    Tamori, Akihiro
    Enomoto, Masaru
    Morikawa, Hiroyasu
    Kozuka, Ritsuzo
    Teranishi, Yuga
    Motoyama, Hiroyuki
    Kawamura, Etsushi
    Hagihara, Atsushi
    Murakami, Yoshiki
    Le, Thuy T.
    Kawada, Norifumi
    HEPATOLOGY, 2016, 64 : 742A - 742A
  • [37] Efficacy and safety of ruzasvir 60mg and uprifosbuvir 450mg for 12weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection
    Lawitz, Eric
    Poordad, Fred
    Anderson, Leah J.
    Vesay, Michelle
    Kelly, Michelle M.
    Liu, Hong
    Gao, Wei
    Fernsler, Doreen
    Asante-Appiah, Ernest
    Robertson, Michael N.
    Hanna, George J.
    Barr, Eliav
    Butterton, Joan
    Kowdley, Kris, V
    Hassanein, Tarek
    Sahota, Amandeep
    Gordon, Stuart C.
    Yeh, Wendy W.
    JOURNAL OF VIRAL HEPATITIS, 2019, 26 (06) : 675 - 684
  • [38] Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6
    Lawitz, Eric
    Gane, Edward
    Feld, Jordan J.
    Buti, Maria
    Foster, Graham R.
    Rabinovitz, Mordechai
    Burnevich, Eduard
    Katchman, Helena
    Tomasiewicz, Krzysztof
    Lahser, Fred
    Jackson, Beth
    Shaughnessy, Melissa
    Klopfer, Stephanie
    Yeh, Wendy W.
    Robertson, Michael N.
    Hanna, George J.
    Barr, Eliav
    Platt, Heather L.
    JOURNAL OF VIRAL HEPATITIS, 2019, 26 (09) : 1127 - 1138
  • [39] Reliability of hepatitis C virus core antigen assay for detection of viremia in HCV genotypes 1, 2, 3, and 4 infected blood donors: A collaborative study between Japan, Egypt, and Uzbekistan
    Agha, S
    Tanaka, Y
    Saudy, N
    Kurbanov, F
    Abo-Zeid, M
    El-Malky, M
    Khalaf, M
    Ohta, N
    Yoshizawa, H
    Mizokami, M
    JOURNAL OF MEDICAL VIROLOGY, 2004, 73 (02) : 216 - 222
  • [40] A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4
    Vince, Bradley
    Hill, John M.
    Lawitz, Eric J.
    O'Riordan, William
    Webster, Lynn R.
    Gruener, Daniel M.
    Mofsen, Ricky S.
    Murillo, Abel
    Donovan, Eileen
    Chen, Jie
    McCarville, Joseph F.
    Sullivan-Bolyai, John Z.
    Mayers, Douglas
    Zhou, Xiao-Jian
    JOURNAL OF HEPATOLOGY, 2014, 60 (05) : 920 - 927
12345